Promethos Capital LLC Raises Stake in DaVita Inc. (NYSE:DVA)

Promethos Capital LLC lifted its position in shares of DaVita Inc. (NYSE:DVA) by 120.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 28,396 shares of the company’s stock after buying an additional 15,490 shares during the period. DaVita accounts for approximately 1.5% of Promethos Capital LLC’s portfolio, making the stock its 28th largest holding. Promethos Capital LLC’s holdings in DaVita were worth $3,935,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. 8 Knots Management LLC acquired a new position in shares of DaVita during the 4th quarter valued at about $89,504,000. Doma Perpetual Capital Management LLC purchased a new stake in shares of DaVita during the 4th quarter valued at $53,076,000. Harvard Management Co. Inc. acquired a new stake in shares of DaVita during the 2nd quarter worth $55,115,000. Norges Bank purchased a new position in shares of DaVita in the 4th quarter worth $36,626,000. Finally, Allianz Asset Management GmbH boosted its holdings in DaVita by 63.9% in the fourth quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after acquiring an additional 213,992 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares in the company, valued at approximately $12,137,038.31. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now owns 241,945 shares of the company’s stock, valued at $36,299,008.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 173,482 shares of company stock valued at $27,387,069. Insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. TD Cowen boosted their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Truist Financial increased their target price on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. Finally, UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, DaVita presently has an average rating of “Hold” and an average target price of $157.00.

DaVita Price Performance

Shares of NYSE DVA opened at $163.14 on Friday. The business has a 50 day moving average price of $146.73 and a two-hundred day moving average price of $140.69. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $166.04. The firm has a market cap of $14.31 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.95 and a beta of 0.87. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.08 earnings per share. Sell-side analysts expect that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.